Buy Sparex capsules 200 mg 30 pcs
  • Buy Sparex capsules 200 mg 30 pcs


1211 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Sparex - myotropic antispasmodic action, has a direct effect on the smooth muscles of the gastrointestinal tract (mainly the large intestine). Eliminates spasm without affecting the normal intestinal motility. Inhibits phosphodiesterase. Stabilizes the level of cyclic adenosine monophosphoric acid. Does not possess anticholinergic action.


In adults
Spasm of the gastrointestinal tract (including caused by an organic disease), intestinal colic, biliary colic, irritable bowel syndrome.

In children older than 12 years
Functional disorders of the gastrointestinal tract, accompanied by abdominal pain.


Active substance: Mebeverinee hydrochloride 200 mg;

Excipients: colloidal silicon dioxide (Aerosil), hypromellose (hydroxypropylmethylcellulose brand Benecel MP 874), povidone (plasdone K 90, kollidon 90 F), magnesium stearate

Mebeverine is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Sparex Canonpharma Russia capsules
Niaspam Sun Pharmaceutical Industries Ltd India capsules
Duspatalin Abbott USA pills
Duspatalin Abbott USA capsules

No customer reviews for the moment.

Write your review

Write your review


Dosage and Administration

For oral administration.

Capsules need to be swallowed, drinking plenty of water (at least 100 ml). Capsules should not be chewed, since their shell provides a long-term release of the drug.

Take one capsule 2 times a day 20 minutes before meals, one capsule in the morning and one capsule in the evening.

The duration of the drug is not limited.

If the patient has forgotten to take one or more doses, the drug should be continued with the next dose. One or more missed doses should not be taken in addition to the usual dose.

Use in special patient groups

Dose adjustment is not required for elderly patients, patients with hepatic and / or renal insufficiency.

Adverse reactions

The reported side effects were spontaneous and there is not enough data available to accurately estimate the frequency of cases.

Allergic reactions were observed mainly on the part of the skin, but other manifestations of allergy were also noted.

On the part of the skin and subcutaneous tissues: urticaria, angioedema, including the face, exanthema.

On the part of the immune system: hypersensitivity reactions (anaphylactic reactions).


Hypersensitivity to any component of the drug.

Age up to 18 years (due to the lack of data on efficacy and safety).

Pregnancy (due to lack of data), breastfeeding period.

Drug interactions

Conducted only studies on the interaction of Mebeverine with ethanol. Animal studies have demonstrated the absence of any interaction between Mebeverine and ethanol.

Pregnancy and Lactation


There are only very limited data on the use of Mebeverine in pregnant women. The drug is not recommended for use during pregnancy.

Breastfeeding period

Information on the excretion of Mebeverine or its metabolites in breast milk is not enough. Do not take the drug during breastfeeding.


Clinical data on the effect of the drug on fertility in men or women are not available, however, animal studies have not demonstrated adverse effects of the drug.

Special instructions

Influence on ability to drive motor transport and control mechanisms

Niaspam does not affect the ability to drive and engage in potentially hazardous activities that require increased concentration and psychomotor speed.


Symptoms: theoretically, in case of an overdose, the excitability of the central nervous system may increase. In cases of overdose of Mebeverine, the symptoms were either absent or insignificant and, as a rule, quickly reversible. The observed symptoms of overdose were neurological and cardiovascular.

Treatment: symptomatic treatment is recommended. Gastric lavage is necessary only if intoxication is detected within approximately one hour after taking several doses of the drug. Absorption reduction measures are not required. The specific antidote is unknown.

  • Active ingredient: Mebeverine

Studies and clinical trials of Mebeverine (Click to expand)

  1. A validated chiral HPLC method for the determination of mebeverine HCl enantiomers in pharmaceutical dosage forms and spiked rat plasma
  2. Evaluation of capillary supercritical fluid chromatography with mass spectrometric detection for the analysis of a drug (mebeverine) in a dog plasma matrix
  3. Determination of two mebeverine metabolites, mebeverine alcohol and desmethylmebeverine alcohol, in human plasma by a dual stable isotope-based gas chromatographic-mass spectrometric method
  4. Development and validation of stability indicating HPLC and HPTLC methods for determination of sulpiride and mebeverine hydrochloride in combination
  5. Potentiometric flow injection analysis of mebeverine hydrochloride in serum and urine
  6. Spectrophotometric determination of benzydamine HCl, levamisole HCl and mebeverine HCl through ion-pair complex formation with methyl orange
  7. Quantitative determination of mebeverine HCl by NMR chemical shift migration
  8. Reversed-phase high-performance thin-layer chromatography of mebeverine hydrochlordie and related compounds
  9. Development of a standardized analysis strategy for basic drugs using ion-pair extraction and high-performance liquid chromatography : VIII. Method construction for the determination of mebeverine in tablets and biological fluids
  10. Identification of mebeverine acid as the main circulating metabolite of mebeverine in man
  11. Application of first-derivative UV-spectrophotometry, TLC-densitometry and liquid chromatography for the simultaneous determination of mebeverine hydrochloride and sulpiride
  12. Mebeverine alters small bowel motility in irritable bowel syndrome
  13. Mebeverine decreases mass movements and stool frequency in lactulose-induced diarrhoea
  14. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients
  15. Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial)
  16. Treatment patterns and health care costs of mebeverine-treated IBS patients: a case-control study
  17. Spectrophotometric determination of mebeverine hydrochloride
  18. Quantitative analysis of mebeverine in dosage forms by HPLC
  19. Lack of bioavailability of mebeverine even after pretreatment with pyridostigmine
  20. First Derivative Synchronous Fluorescence Spectroscopy for the Simultaneous Determination of Sulpiride and Mebeverine Hydrochloride in Their Combined Tablets and Application to Real Human Plasma
  21. Process, optimization and characterization of mebeverine hydrochloride loaded guar gum microspheres for irritable bowel syndrome
  22. Quantitative HPLC analysis of mebeverine, mesalazine, sulphasalazine and dispersible aspirin stored in a Venalink monitored dosage system with co-prescribed medicines
  23. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine
  24. Design and Formulation of Mebeverine HCl Semisolid Formulations for Intraorally Administration

Customers who bought this product also bought:


Price $21.65

8 other products in the same category: